Related Experiment Video
Updated: Jan 15, 2026

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Managing tuberculosis infection among migrants from high-incidence tuberculosis countries: challenges, strategies and
Salvatore Rotundo1, Francesca Serapide2,3, Gabriella d'Ettorre4
1Department of Medical and Surgical Sciences, "Magna Graecia" University, Catanzaro, Italy. srotundo91@gmail.com.
Abstract:
Tuberculosis (TB) remains a significant global health challenge, especially in countries with low TB incidence, exacerbated by the influx of migrants from high TB-burden regions. This paper reviews the challenges and strategies for managing TB infection (TBI) among migrants. Challenges in screening and treating TBI among migrants include diagnostic limitations of available tests which are tuberculin skin test (TST) and interferon-gamma release assay (IGRA), socioeconomic barriers, cultural beliefs and mobility. Recommendations vary among guidelines, ranging from proactive screening to targeted approaches. We addressed the issue of two-step testing, discussing the use of an initial TST followed by IGRA confirmation, with consideration of BCG vaccination status and TB exposure history. Treatment options for TBI include isoniazid monotherapy and rifamycin-based regimens in most cases, with varying preferences across guidelines. Challenges in TBI treatment include hepatotoxicity and adherence issues, particularly among migrants. Overall, a comprehensive approach addressing socioeconomic, cultural, and structural factors is crucial for effective TBI management among migrants. Collaboration between healthcare providers, policymakers and migrant communities is essential for developing culturally sensitive screening and treatment protocols. Further research is needed to evaluate the efficacy and feasibility of different screening and treatment strategies, particularly among migrant populations.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...

